Bax/Bcl-2 Expression in Pediatric Acute Lymphoblastic Leukemia
Researchers sought to determine the impact of Bax and Bcl-2 expression in pediatric patients with acute lymphoblastic leukemia after completing induction chemotherapy.
Researchers sought to determine the impact of Bax and Bcl-2 expression in pediatric patients with acute lymphoblastic leukemia after completing induction chemotherapy.
The combination produced an overall response rate of 99%, and the 5-year remission rate was 76%.
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Researchers sought to determine the relevance of the RAD21 gene in pediatric lymphoblastic leukemia or lymphoma.
Survival for adolescent and young adult leukemia survivors remained below general population at up to 30 years of follow-up.
There was no significant difference in transplant-related mortality or overall survival.
Researchers sought to determine whether tisagenlecleucel is safe and effective in patients younger than 3 years old with relapsed/refractory ALL.
Researchers sought to determine whether monitoring SAA levels would be a helpful strategy for determining therapy efficacy in infants with ALL.
Researchers sought to improve the understanding of cGVHD in pediatric patients with ALL after they receive allo-HSCT.
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.